Braslia, Brazil : Brazil became the first South American country Monday to authorize the world's first-ever dengue fever vaccine, which its French manufacturer says has the potential to save hundreds of lives here.
The tropical disease, a flu-like illness carried by mosquitoes, killed 839 people this year in Brazil and infected more than 1.5 million.
The sprawling South American country's decision to allow the new vaccine, called Dengvaxia, is a coup for French pharmaceutical giant Sanofi, which has now gotten the green light from regulators in three countries.
Mexico became the first country to allow the vaccine on December 9, and the Philippines followed suit last week.
Sanofi has requested regulatory approval in 20 countries across Asia and Latin America.
The vaccine is a potential "blockbuster" drug for the company, which estimates it could generate more than $1 billion a year in revenue.
The Brazilian government said regulators must still set a price per dose, a process that takes about three months on average.
A separate review would have to be carried out for the vaccine to be incorporated in the national vaccination plan, a health ministry official told AFP.
Scientists have long been stumped by dengue, which has four separate strains.
Clinical tests -- carried out on 40,000 people from 15 countries -- have found Dengvaxia can immunize two-thirds of people aged nine years and older, rising to 93 percent for the more severe form of the disease, dengue hemorrhagic fever.
Dengue infects as many as 400 million people per year, and the deadliest form kills 22,000 per year, says the World Health Organization.
It was once considered a disease of the tropics, endemic in only nine countries.
But globalization, urbanization, climate change and air travel are helping it to move into more temperate zones. It is now endemic in more than 100 countries.
The WHO says cases have risen 30-fold over the last 50 years, with more than half the world's population potentially at risk.
The 20 countries where Sanofi Pasteur hopes for regulatory approval have a total population of two billion people -- 200 million of them in Brazil.
The tropical disease, a flu-like illness carried by mosquitoes, killed 839 people this year in Brazil and infected more than 1.5 million.
The sprawling South American country's decision to allow the new vaccine, called Dengvaxia, is a coup for French pharmaceutical giant Sanofi, which has now gotten the green light from regulators in three countries.
Sanofi has requested regulatory approval in 20 countries across Asia and Latin America.
Advertisement
The Brazilian government said regulators must still set a price per dose, a process that takes about three months on average.
Advertisement
Scientists have long been stumped by dengue, which has four separate strains.
Advertisement
Dengue infects as many as 400 million people per year, and the deadliest form kills 22,000 per year, says the World Health Organization.
Advertisement
But globalization, urbanization, climate change and air travel are helping it to move into more temperate zones. It is now endemic in more than 100 countries.
Advertisement
The 20 countries where Sanofi Pasteur hopes for regulatory approval have a total population of two billion people -- 200 million of them in Brazil.
COMMENTS
Advertisement
Vinicius-less Brazil Lose To 10-Man Uruguay On Penalties In Copa America Quarter-Finals Ex-Brazil President Jair Bolsonaro Accused In Saudi Jewel Scandal Brazil Held By Colombia In Copa America, To Face Uruguay Quarter-Final 25,000 Aspirants For Airport Jobs Paying Rs 22,000: A Mumbai Stampede Scare 4 Top Leaders Quit Ajit Pawar's Party In Major Setback After Poll Drubbing Trump's Running Mate Calls UK "Truly Islamist State With Nuclear Weapons" MCom, BBA, BCom: The Many Aspirants For Handyman's Job At Mumbai Airport Why Donald Trump Picked JD Vance As His Vice President Candidate Rs 1.98 Crore Relief In Mercedes Hit-And-Run, Car Was Driven By Minor Track Latest News Live on NDTV.com and get news updates from India and around the world.